PFE · Pfizer Inc
United States · RS rating 88 · As of 2026-11-03
| Price | 30.00 USD |
|---|---|
| 1-day change | -2.2% |
| RS rating (overall / 1M / 3M / 12M) | 88 / 81 / 87 / 72 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 44 / 63 / 30 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | -146.8% |
| Sales growth Q/Q | +5.4% |
| Distance from 52-week high | +2.2% |
| Market cap (USD) | $151.7B |